share_log

君聖泰醫藥-B：截至二零二四年九月三十日止月份之股份發行人的證券變動月報表

HIGHTIDE-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024

HKEX ·  Oct 2, 2024 11:24

Summary by Moomoo AI

君圣泰医药-B（HIGHTIDE-B）於2024年10月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年9月30日的股份變動情況。報告顯示，公司的法定/註冊股本及已發行股份數量在該月份保持不變，法定/註冊股本總額為100,000美元，已發行股份總數為514,770,668股。該報告亦確認，君圣泰医药-B在當月進行的所有證券發行或庫存股份出售或轉讓均已獲得董事會授權，並符合所有適用的上市規則、法律及其他監管規定。執行董事兼行政總裁劉利平博士為本次報告的呈交者。
君圣泰医药-B（HIGHTIDE-B）於2024年10月2日向香港交易及結算所有限公司提交了最新的證券變動月報表，報告截至2024年9月30日的股份變動情況。報告顯示，公司的法定/註冊股本及已發行股份數量在該月份保持不變，法定/註冊股本總額為100,000美元，已發行股份總數為514,770,668股。該報告亦確認，君圣泰医药-B在當月進行的所有證券發行或庫存股份出售或轉讓均已獲得董事會授權，並符合所有適用的上市規則、法律及其他監管規定。執行董事兼行政總裁劉利平博士為本次報告的呈交者。
HIGHTIDE-B submitted the latest Monthly Securities Report on Share Changes to the Hong Kong Exchanges and Clearing Limited on October 2, 2024, reporting the share changes as of September 30, 2024. The report indicates that the company's statutory/registered share capital and the total number of issued shares remained unchanged in that month, with a total statutory/registered share capital of $100,000 and a total number of issued shares of 514,770,668 shares. The report also confirms that all securities issuances, treasury shares sales, or transfers conducted by HIGHTIDE-B in the same month have been authorized by the board of directors and comply with all applicable listing rules, laws, and other regulatory requirements. Dr. Liu Liping, Executive Director and CEO, was the submitter of this report.
HIGHTIDE-B submitted the latest Monthly Securities Report on Share Changes to the Hong Kong Exchanges and Clearing Limited on October 2, 2024, reporting the share changes as of September 30, 2024. The report indicates that the company's statutory/registered share capital and the total number of issued shares remained unchanged in that month, with a total statutory/registered share capital of $100,000 and a total number of issued shares of 514,770,668 shares. The report also confirms that all securities issuances, treasury shares sales, or transfers conducted by HIGHTIDE-B in the same month have been authorized by the board of directors and comply with all applicable listing rules, laws, and other regulatory requirements. Dr. Liu Liping, Executive Director and CEO, was the submitter of this report.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated